Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
![[177Lu]Lu-zolbetuximab in Glioblastoma, IDH-Wildtype: NCT07648823 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_B_86_48077a7b89.jpg)
9 min read
[177Lu]Lu-zolbetuximab in Glioblastoma, IDH-Wildtype: NCT07648823 Clinical Landscape Report 2026
16 September 2026
NCT07648823 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ropeginterferon alfa-2b-NJFT in Acute Myeloid Leukemia: NCT07646821 Clinical Landscape Report 2026
16 September 2026
NCT07646821 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gamgertamig in Multiple Myeloma: NCT07648459 Clinical Landscape Report 2026
16 September 2026
NCT07648459 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Plasma Cell Leukemia: NCT07652905 Clinical Landscape Report 2026
16 September 2026
NCT07652905 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gefitinib in Cervical Squamous Cell Carcinoma: CTRI/2026/06/112765 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/112765 clinical landscape for Cervical Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
BCMA-CAR-T cell-derived exosomes in BCMA Positive Multiple Myeloma: NCT07652138 Clinical Landscape Report 2026
16 September 2026
NCT07652138 clinical landscape for BCMA Positive Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in AIDS-Related Lymphoma: NCT07649304 Clinical Landscape Report 2026
16 September 2026
NCT07649304 clinical landscape for AIDS-Related Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant human thrombopoietin (Sunshine Pharmaceutical) in Thrombocytopenia: NCT07649395 Clinical Landscape Report 2026
16 September 2026
NCT07649395 clinical landscape for Thrombocytopenia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HBM-7020 in Sjogren's Syndrome: NCT07649265 Clinical Landscape Report 2026
16 September 2026
NCT07649265 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Uterine Cervical Cancer: NCT07653503 Clinical Landscape Report 2026
16 September 2026
NCT07653503 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Recurrent Endometrial Cancer: NCT07652515 Clinical Landscape Report 2026
16 September 2026
NCT07652515 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT07652242 Clinical Landscape Report 2026
16 September 2026
NCT07652242 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.